Financial reports
10-Q
2024 Q1
Quarterly report
7 May 24
ARS
2023 FY
Annual report to shareholders
29 Apr 24
10-K
2023 FY
Annual report
28 Feb 24
10-Q
2023 Q3
Quarterly report
6 Nov 23
10-Q
2023 Q2
Quarterly report
8 Aug 23
10-Q
2023 Q1
Quarterly report
9 May 23
10-K
2022 FY
Annual report
23 Feb 23
10-Q
2022 Q3
Quarterly report
3 Nov 22
10-Q
2022 Q2
Quarterly report
4 Aug 22
Current reports
8-K
Entry into a Material Definitive Agreement
7 May 24
8-K
Madrigal Pharmaceuticals Reports First-Quarter 2024 Financial Results and Provides Corporate Updates
7 May 24
8-K
Other Events
2 Apr 24
8-K
Entry into a Material Definitive Agreement
20 Mar 24
8-K
Regulation FD Disclosure
14 Mar 24
8-K
Departure of Directors or Certain Officers
28 Feb 24
8-K
Madrigal Pharmaceuticals Provides Corporate Updates and Reports Fourth Quarter and Full
28 Feb 24
8-K
Other Events
8 Jan 24
8-K
Madrigal Pharmaceuticals Provides Corporate Updates and Reports Third Quarter 2023
6 Nov 23
8-K
Entry into a Material Definitive Agreement
2 Oct 23
Registration and prospectus
424B3
Prospectus supplement
7 May 24
424B5
Prospectus supplement for primary offering
7 May 24
S-3ASR
Automatic shelf registration
7 May 24
424B5
Prospectus supplement for primary offering
20 Mar 24
424B5
Prospectus supplement for primary offering
18 Mar 24
424B5
Prospectus supplement for primary offering
2 Oct 23
424B5
Prospectus supplement for primary offering
28 Sep 23
S-8
Registration of securities for employees
11 Sep 23
424B3
Prospectus supplement
8 Aug 23
424B5
Prospectus supplement for primary offering
9 May 23
Proxies
DEFA14A
Additional proxy soliciting materials
29 Apr 24
DEF 14A
Definitive proxy
29 Apr 24
DEFA14A
Additional proxy soliciting materials
1 May 23
DEF 14A
Definitive proxy
1 May 23
PRE 14A
Preliminary proxy
21 Apr 23
DEFA14A
Additional proxy soliciting materials
2 May 22
DEF 14A
Definitive proxy
2 May 22
DEFA14A
Additional proxy soliciting materials
30 Apr 21
DEF 14A
Definitive proxy
30 Apr 21
DEF 14A
Definitive proxy
29 Apr 20
Other
UPLOAD
Letter from SEC
25 Jan 24
CORRESP
Correspondence with SEC
17 Jan 24
UPLOAD
Letter from SEC
3 Jan 24
CORRESP
Correspondence with SEC
14 Dec 23
CORRESP
Correspondence with SEC
8 Dec 23
UPLOAD
Letter from SEC
21 Nov 23
CT ORDER
Confidential treatment order
12 Mar 19
EFFECT
Notice of effectiveness
25 Jul 17
CORRESP
Correspondence with SEC
21 Jul 17
UPLOAD
Letter from SEC
21 Jul 17
Ownership
4
Robert E. Waltermire
18 Jun 24
4
Robert E. Waltermire
14 Jun 24
144
Notice of proposed sale of securities
14 Jun 24
144
Notice of proposed sale of securities
14 Jun 24
4
FRED B CRAVES
13 Jun 24
144
Notice of proposed sale of securities
13 Jun 24
144
Notice of proposed sale of securities
12 Jun 24
144
Notice of proposed sale of securities
11 Jun 24
144
Notice of proposed sale of securities
6 Jun 24
4
Robert E. Waltermire
23 May 24